Diabetes is one of the most alarming issues all over the world. At the moment, nearly 463 million patients are dealing with it. By 2045, that number could explode to approx. 700 million, according to the International Diabetes Foundation. On top of that, millions more are pre-diabetic and aren’t even aware. The good news is psychedelics may be able to help combat issues such as diabetes, and even obesity, which could be a major catalyst for companies such as PharmaTher Holdings Ltd. (CSE: PHRM)(OTCQB: PHRRF), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), Compass Pathways (NASDAQ:CMPS), Seelos Therapeutics Inc. (NASDAQ:SEEL), and Cybin Inc. (NEO:CYBN)(OTC:CLXPF).
In fact, according to PharmaTher Holdings’ latest patent application, the company, “identifies protein bindings and interactions with ketamine leading to the discovery of ketamine as a potential treatment for Type 2 diabetes and obesity.”
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine
PharmaTher Holdings Ltd. (CSE: PHRM)(OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity, based on the evaluation of the Company’s drug repurposing artificial intelligence platform, panaceAI™. PharmaTher is also advancing research with panaceAI™ to evaluate repurposing opportunities with DMT, MDMA, and LSD for future clinical development and partnering opportunities.
The patent application, entitled “Use of Ketamine in the Treatment of Diabetes and Obesity,” identifies protein bindings and interactions with ketamine leading to the discovery of ketamine as a potential treatment for Type 2 diabetes and obesity. The Company has submitted an Investigational New Drug application with the U.S. Food and Drug Administration (“FDA”) for the initiation of a Phase 2 clinical trial to evaluate ketamine in the treatment of Parkinson’s disease. Upon the FDA accepting the IND, PharmaTher will leverage the IND to expand the clinical development of ketamine in depression, amyotrophic lateral sclerosis (Lou Gehrig’s disease), pain and obesity-related disorders.
PharmaTher uses its drug repurposing AI platform, panaceAI™, to expand on the Company’s patent portfolio of novel uses of DMT, MDMA and LSD. PharmaTher’s objective is to discover novel uses of these psychedelics and incorporate them into the Company’s proprietary microneedle patch delivery system currently being evaluated at the Terasaki Institute. The Company seeks to commercialize the product developments either internally or partner with life sciences companies seeking to expand their product portfolio with psychedelics. PharmaTher recently used panaceAI™ to discover novel uses of psilocybin in the potential treatment of certain cancers, which led to the sale of the Company’s psilocybin intellectual property portfolio to Revive Therapeutics Ltd. (CSE: RVV, OTC: RVVTF) for a consideration of up to CAD $10 million.
Fabio Chianelli, CEO of PharmaTher, commented: “We continue to focus on building our patent and product portfolio of prescription-based psychedelics through our drug repurposing and delivery methods for unmet medical needs,” Fabio Chianelli, CEO of PharmaTher. “Our strategy is to investigate ketamine in FDA Phase 2 clinical trials for Parkinson’s disease and depression and with panaceAI™, we aim to find new uses of psychedelics, such as ketamine, psilocybin, DMT, MDMA and LSD, and incorporate them into our proprietary microneedle patch delivery system. We are well-positioned to unlock value in our patent portfolio consisting of novel uses, formulations and delivery systems for psychedelics as a pharmaceutical prescription.”
Other related developments from around the markets include:
Mind Medicine Inc., a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions. The study used data from 194 MDMA administrations in ten randomized placebo-controlled studies in healthy subjects conducted by the Liechti Lab at the University Hospital Basel, Switzerland.
Compass Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health , welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin.
Seelos Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it will participate in the 2021 RBC Capital Markets Global Healthcare Conference , May 18-20, 2021. Raj Mehra, Ph.D., Chairman and CEO, will present on Tuesday, May 18th at 4:50pm ET and host 1x1 meetings on May 18th and 19th. For more information and to register for the webcast: 2021 RBC Capital Markets Global Healthcare Conference .
Cybin Inc. announced plans to advance the pre-clinical work for its orally dissolving tablet formulation of CYB003 and its inhaled formulation of CYB004, two of the Company’s deuterated tryptamine development candidates. These studies are part of the required U.S. Food and Drug Administration enabling trials for investigational new drug applications. Upon successful completion, the results of the IND-enabling studies will be included in the submissions to the FDA, as well as to other regulatory bodies, such as Health Canada and European Medical Association. The candidates would then advance into Phase 1 human clinical trials for specified psychiatric conditions. Labcorp Drug Development will serve as the pre-clinical research organization for Cybin.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for PharmaTher Holdings Ltd. by a third party. We own ZERO shares of PharmaTher Holdings Ltd. Please click here for full disclaimer.
Contact Information:
2818047972
ty@Lifewatermedia.com